The findings of Cao et al.48suggested that crizotinib, which is also an inhibitor of ROS‐1 (ROS protooncogene 1, receptor tyrosine kinase), can be an option to improve overall survival and quality of life of patients with metastatic ROS1‐fusion MM. This evidence concerns the gene ROS1 and Miyoshi myopathy.